Weight Watchers International Stock Earnings Reports

WeightWatchers is executing a multiyear transformation to become the preferred weight-health destination in a GLP-1 era by combining FDA-approved medications with its behavioral/community programming. Key Q1 2026 financial and operating takeaways: Clinical (Med+) momentum — Clinical subscribers reached 197k (51% sequential growth) and Clinical subscription revenue grew 32% YoY; Clinical ARPU remains >4x Behavioral ARPU and Clinical is expected to be ~25–30% of 2026 revenue. Core+ returned to growth with 537k subscribers (up 6% YoY) and Core+ ARPU is nearly 2x Core, helping overall ARPU rise 13% YoY to $20.59. Total Q1 revenue was $168M (down 10% YoY) while adjusted gross margin held near record at 73.6%. Adjusted EBITDA was a $1.8M loss for Q1; the company reaffirmed full-year 2026 guidance of $620–635M revenue and $105–115M adjusted EBITDA and expects to generate cash through the remainder of 2026. Liquidity/debt actions: $121M cash on hand at quarter end and planned Q2 use of $37M to reduce term loan principal (reducing annual interest expense ~ $4M). Marketing was front-loaded in Q1 to drive Med+/GLP-1 awareness (helping Clinical growth and new-member acquisition), and management expects more balanced marketing and seasonal normalization across the rest of 2026. Operational focus remains on scaling Clinical efficiently (workflow automation, tech enablement), stabilizing Behavioral via upgraded virtual offerings and medically tailored programs (menopause, GLP-1 success), and continuing margin discipline. Management highlights competitive advantage from combining meds with structured behavioral support, but acknowledges Behavioral secular headwinds and that the transformation will take time.